Open Access

Progressive decay of Ca2+ homeostasis in the development of diabetic cardiomyopathy

  • Shu-Mei Zhao1,
  • Yong-Liang Wang1,
  • Chun-Yan Guo1,
  • Jin-Ling Chen1 and
  • Yong-Quan Wu1Email author
Cardiovascular Diabetology201413:75

DOI: 10.1186/1475-2840-13-75

Received: 25 December 2013

Accepted: 29 March 2014

Published: 9 April 2014



Cardiac dysfunction in diabetic cardiomyopathy may be associated with abnormal Ca2+ homeostasis. This study investigated the effects of alterations in Ca2+ homeostasis and sarcoplasmic reticulum Ca2+-associated proteins on cardiac function in the development of diabetic cardiomyopathy.


Sprague–Dawley rats were divided into 4 groups (n = 12, each): a control group, and streptozotocin-induced rat models of diabetes groups, examined after 4, 8, or 12 weeks. Evaluations on cardiac structure and function were performed by echocardiography and hemodynamic examinations, respectively. Cardiomyocytes were isolated and spontaneous Ca2+ spark images were formed by introducing fluorescent dye Fluo-4 and obtained with confocal scanning microscopy. Expressions of Ca2+-associated proteins were assessed by Western blotting.


Echocardiography and hemodynamic measurements revealed that cardiac dysfunction is associated with the progression of diabetes, which also correlated with a gradual but significant decline in Ca2+ spark frequency (in the 4-, 8- and 12-week diabetic groups). However, Ca2+ spark decay time constants increased significantly, relative to the control group. Expressions of ryanodine receptor 2 (RyR2), sarcoplasmic reticulum Ca2+-2ATPase (SERCA) and Na+/Ca2+ exchanger (NCX1) were decreased, together with quantitative alterations in Ca2+regulatory proteins, FKBP12.6 and phospholamban progressively and respectively in the diabetic rats.


Ca2+ sparks exhibited a time-dependent decay with progression of diabetic cardiomyopathy, which may partly contribute to cardiac dysfunction. This abnormality may be attributable to alterations in the expressions of some Ca2+-associated proteins.


Spontaneous Ca2+ spark Cardiac dysfunction Calcium-associated protein Diabetic cardiomyopathy


Ca2+-induced Ca2+ release plays an important role in the translation of electrical signals to physical contraction in cardiomyocytes, known as excitation-contraction coupling. A small amount of Ca2+ influx through L-type Ca2+ channels can activate a further discharge of Ca2+ from the sarcoplasmic reticulum (SR) via ryanodine receptor 2 (RyR2), resulting in an increase in global intracellular Ca2+ which activates contraction [1]. Elementary Ca2+ release events occur spontaneously as clusters, termed Ca2+ sparks [2]. During diastole, myocardial relaxation results from the reuptake of Ca2+ into the SR via Ca2+-ATPase (SERCA) on the SR, and concurrently Ca2+ is pumped out of the cardiomyocytes via the Na+/Ca2+ exchanger (NCX). An imbalance of Ca2+ flux may induce pathological conditions such as arrhythmia and decreased contractility of the cardiomyocytes. It has been reported that a certain portion of the contractile deficit in heart failure is due to an impairment of Ca2+ homeostasis [3, 4].

Diabetic cardiomyopathy was initially recognized by Rubler et al. [5] in diabetic patients, who exhibited defects in myocardial contraction and relaxation, and increased morbidity and mortality. Cardiac dysfunction in diabetic models may result from a variety of metabolic and biochemical abnormalities, including abnormal Ca2+ homeostasis. As shown in a previous study, the ability of Ca2+ current to trigger SR Ca2+ release is decreased significantly in diabetic cardiomyocytes. Spontaneous Ca2+ spark frequency and peak amplitude were also both significantly reduced (P < 0.05) in diabetic myocytes compared with the control myocytes [6]. In addition, Choi KM et al. [7] found that the SR Ca2+ release rate and Ca2+ stores were depressed in the cardiomyocytes of type 1 diabetic rats. These changes may account for cardiac dysfunction in diabetic models. However, inconsistent results have been reported. For instance, according to Yaras et al. [8] the maximal amplitude of Ca2+ sparks was not significantly changed, but the spontaneous Ca2+ spark frequency was elevated in diabetic cardiomyocytes, compared with control cells.

It is obvious that the role of Ca2+ involvement in diabetic cardiomyopathy is still not fully known and requires further investigation. As animal models in different diabetic stages have been used in various studies, we hypothesized that the inconsistent results regarding Ca2+ homeostasis were due to different severities and stages of diabetes. Therefore, this study investigated the progressive alterations in Ca2+ homeostasis and expressions of SR Ca2+- associated proteins in the development of diabetes, and the association between Ca2+ homeostasis and cardiac dysfunction in diabetic cardiomyopathy.


Animal models

The Beijing Friendship Hospital Animal Care Committee approved all animal handling protocols. The diabetic rat model was induced with a single intraperitoneal injection of streptozotocin (60 mg/kg diluted in 0.1 M citrate buffer, pH = 4.4; Sigma, USA) in male rats (Sprague–Dawley; 200 ± 20 g). Rats in the control group were given an injection of a matched volume of citrate buffer (0.1 M). Subsequently on day three and day five after the injection, random blood glucose concentrations were measured. Only rats with blood glucose levels ≥16.7 mmol/L on both days were defined as diabetic and used in the study.

Four experimental groups (n = 12, each) consisted of the control group (group A) and the diabetic model rats, examined at 4, 8, or 12 weeks after injection (groups B, C and D, respectively). All the rats were housed (three per cage) in a controlled environment at 20 ± 2°C, 30-70% humidity, and a 12:12 h light–dark cycle, and given standard chow and water ad libitum. In accordance with the protocol, all diabetic model rats were euthanized prior to the experiments at the assigned time points. Control rats were euthanized at the twelfth week after an injection with citrate buffer.

Echocardiographic measurements

Echocardiography was performed to evaluate cardiac structure and function in all animals involved in the study (n = 12, in each group). The rats were weighed and anesthetized with 10% chloral hydrate at 0.3 mL/100 g body weight [9]. Two-dimensional and M-mode echocardiographic measurements were carried out with a VEVO 770 high-resolution in vivo imaging system (VisualSonics, Toronto, Canada). The transthoracic echocardiography images were obtained via long- and short-axis views using standard echocardiography techniques [10]. Cardiac structure was principally evaluated by the left ventricular end diastolic and systolic diameters. The left ventricular systolic function was assessed according to ejection fraction and fractional shortening, and the left ventricular diastolic function was determined by Doppler waveforms of mitral inflows, which were obtained from an apical four-chamber. The variables included the peak early diastolic filling velocity (E wave), the peak late diastolic filling velocity (A wave), and the ratio of the peak early-to late-filling velocity (E/A).

Hemodynamic measurements

To assess the hemodynamic condition, an ultra-miniature catheter connected to a polygraph instrument (BL-420, TaiMeng, ChengDu, China) was inserted into the carotid artery, and then to the left ventricle of the anesthetized animals (n = 6, in each group). After a 5-min period of stabilization, the parameters were acquired and recorded. The myocardial contractility was assessed according to the left ventricular systolic peak pressure (LVPSP) and the maximum rate of ascending pressure change in the left ventricle (+dP/dtmax). Myocardial relaxation was evaluated according to the left ventricular end-diastolic pressure (LVEDP) and the maximum descending rate of left ventricular pressure (−dP/dtmax) [11]. The hearts were then removed and stored at −80°C for further study.

Examination of Ca2+ homeostasis in cardiomyocytes

Ventricular myocytes were isolated from the rats (n = 6, in each group) as described previously [12]. In brief, the hearts were cannulated, and perfused for 10 minutes at 2 mL/min (37°C) with oxygenated Ca2+-free buffer, containing 145 mM NaCl, 5 mM KCl, 1.2 mM MgSO4, 1.4 mM Na2HPO4, 0.4 mM NaH2PO4, 5 mM HEPES, and 10 mM glucose; pH 7.4, adjusted with NaOH. Then the hearts were perfused with an enzyme solution, containing 0.6 mg/mL collagenase type II (Invitrogen, USA) for about 15 min. The ventricular muscle tissue was cut into small pieces, and the ventricular myocytes were released by agitating the cell/tissue suspension. After filtration through a nylon mesh, Ca2+ was gradually reintroduced up to 1.8 mM in the cell suspension. The ventricular myocytes were then ready to be used in further studies.

For the Ca2+ spark imaging, cardiomyocytes were incubated with 10 μM Fluo-4 AM (Invitrogen, USA) in a normal Tyrode’s solution for 5 min at 37°C, and transferred into a recording chamber. Cells were perfused with the Tyrode’s solution for 20 min for de-esterification. SR Ca2+ load was estimated by a rapid application of 10 mM caffeine via a nearby pipette. To control the rest potentiation, experiments were performed after about 30 minutes, upon reintroduction of Ca2+ to a concentration of 1.8 mM in each group. Confocal line-scan imaging was performed using a Leica SP5 confocal microscope (Germany, 40 ×, 1.25 NA) with an excitation at 488 nm. Line-scan images were acquired at a sampling rate of 1.43 ms per line, along the longitudinal axis of the cell. Digital image processing was performed using MATLAB 7.1 (Math Works). For a minimal detection of Ca2+ sparks, the criteria was set at greater than 3.8× the standard deviation (SD) of the background noise over the mean background noise, and Ca2+ sparks were automatically counted with the Sparkmaster Plug-in for Image [13].

Western blot analysis

Western blot analyses (n = 6, in each group) were conducted as previously described [14] to assess the expressions of the Ca2+-associated proteins RyR2, SERCA, NCX1, FKBP12.6, and phospholamban (PLB), and the phosphorylation status of PLB at serine-16 (PLB-Ser16) and threonine-17 (PLB-Thr17). In brief, the heart tissue was homogenized in a cold Tris–HCl buffer (120 mM NaCl, 1.0%, Triton X-100, 20 mM Tris–HCl, pH 7.5, 10% glycerol, 2 mM EDTA, protease inhibitor cocktail). Total protein was quantified using a BCA protein assay kit as required (CW Bio Tech, 02912E, China). Equal amounts of protein (40 μg) were separated by SDS-PAGE. After electrophoresis, proteins were transferred to a polyvinylidene fluoride membrane and blocked with Tris buffered saline containing 5% skim milk powder and 0.05% Tween 20. Then the corresponding primary antibodies, RyR2 (1:1000, Abcam, USA), SERCA (1:1000, Abcam, USA), NCX1 (1:300, Santa Cruz, USA), PLB (1:1000, Abcam, USA), PLB-Thr17 (1:300, Santa Cruz, USA), PLB-Ser16 (1:300, Santa Cruz, USA), and FKBP12.6 (1:1000, R&D, USA) were added in series. The membranes were incubated with the diluted antibody preparations overnight at 4°C. After washing, the membranes were incubated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (H + L) and goat anti-mouse IgG (H + L) antibodies (1:104; Jackson, USA) for 40 min at room temperature. The blots were visualized using an enhanced chemiluminescence detection kit (Millipore, USA). Target proteins were quantified and normalized relative to β-actin (1:1000, Zhongshan, China).

Statistical analysis

Data were evaluated by one-way ANOVA expressed as the mean ± SD. When a significant difference was identified by ANOVA, a post-hoc analysis was performed using the Student-Newman-Keuls test. Data were analyzed using SPSS 13.0 software, and a P-value < 0.05 was considered significant.


Descriptive variables of diabetic rats

Blood glucose levels were significantly higher in all diabetic rats (22.62 ± 5.07 mmol/L) compared with the control rats (7.57 ± 1.69 mmol/L; P = 0.00), but were not significantly different among the diabetic groups (P > 0.05; Table 1). Relative to the body weight of the control rats, that of the streptozotocin-induced diabetic rats was significantly lower, and progressively decreased from 4 weeks (group B) to 12 weeks (group D, P < 0.05). Heart weights also decreased during the 12-week development of diabetes, although the difference was statistically significant only in group D compared with the control group (P = 0.013).
Table 1

General characteristics and results of echocardiography



Diabetic models


Group A

Group B

Group C

Group D

Body weight (g)

589.83 ± 37.4

450.3 ± 52.6a

394.8 ± 62.3a

256 ± 46.3a,b,c

Heart weight (mg)

780 ± 105.2

796.8 ± 104.8

748.5 ± 152.2

595.1 ± 59.6a,b,c

Blood glucose (mmol/L)

7.57 ± 1.69

24.83 ± 6.19a

22.25 ± 5.16a

19.47 ± 2.63a


Heart rate (beats/min)

420 ± 15

392 ± 41

409 ± 34

388 ± 30

LVEDD (mm)

11.67 ± 2.06

7.7 ± 0.6a

7.8 ± 0.5a

7.5 ± 0.4a

LVESD (mm)

5.84 ± 1.15

3.9 ± 0.3a

4.3 ± 0.7a

4.1 ± 0.6a

Ejection fraction (%)

76.1 ± 4.2

71.4 ± 4.9

71.7 ± 3.8

67.7 ± 5.18a

Fractional shortening (%)

45.4 ± 2.9

41.6 ± 3.7

39.9 ± 3.1

37.6 ± 2.8a

E wave (cm/s)

129.2 ± 6.74

124.8 ± 6.13

120.9 ± 8.32

112.9 ± 5.93

A wave (cm/s)

76.5 ± 9.1

79.3 ± 10.5

73.1 ± 7.58

79.1 ± 5.39

E/A ratio

1.69 ± 0.2

1.56 ± 0.26

1.65 ± 0.17

1.42 ± 0.14a

LVEDD, left ventricle end-diastolic diameter; LVESD, left ventricle end-systolic diameter.

aP < 0.05 compared with control group; bP < 0.05 compared with group B; cP < 0.05 compared with group C.

Echocardiography measurements

Similar heart rates were observed in all groups (P = 0.627; Table 1). The left ventricular end-diastolic diameters (LVEDD) and left ventricular end-systolic diameters (LVESD) were comparable in all 3 diabetic groups (P > 0.05). With regard to ejection fraction (EF) and fractional shortening (FS), both showed a trend toward gradual decline in the diabetic rats over the 12 weeks, with significant reductions (P < 0.05) appearing at the twelfth week after diabetes was induced (Figure 1). E waves exhibited a downward trend during the progression of diabetes, but there were no significant differences among the diabetic groups (P > 0.05). In group D, there was a slight but substantial decline in E/A ratio compared with that in control group (P = 0.027).
Figure 1

Echocardiography of the study subjects with ejection fraction and fractional shortening. (a) Representative echocardiograph. (b) Representative measurement of the parameters. (c) Ejection fraction (EF) values of groups A-D. (d) Fractional shortening (FS) values of groups A-D. *P < 0.05, compared with group A.

Hemodynamic measurements

As diabetes progressed over the experimental period, LVPSP decreased gradually from group B (4 weeks) to group D (12 weeks; Figure 2e). Compared with the controls, LVPSP was reduced significantly in group D (P = 0.009), which was consistent with the marked drops in EF and FS. Concurrently, the left ventricular end-diastolic pressure (LVEDP) increased gradually. Relative to the control rats, a significant increase in LVEDP first appeared in group C (8 weeks, P = 0.003, Figure 2f), which was earlier than that of the significant difference in LVPSP. Both + dP/dtmax and –dP/dtmax began to decrease significantly in group C, and were sustained in group D, which suggested marked impairments of both systolic and diastolic capabilities of the diabetic myocardium (Figure 2g and h).
Figure 2

Cardiac hemodynamics. The representative hemodynamic curves recorded by polygraphy: (a) Group A; (b) Group B; (c) Group C; (d) Group D. X-axes represent time in second. The parameters: left ventricular systolic peak pressure (LVPSP) (e), left ventricular end-diastolic pressure (LVEDP) (f), +dP/dtmax(g), −dP/dtmax(h) in groups A-D. ±dP/dtmax: maximal ascending and descending rates of left ventricular pressure. *P < 0.05, compared with group A; #P < 0.05, compared with group B; P < 0.05, compared with group C.

Maintenance of Ca2+ homeostasis

Over the 12-week progression of diabetes, there were alterations in the properties of Ca2+ sparks (Figure 3). The frequency of Ca2+ sparks showed a significant decline, beginning at 4 weeks (group B), and was sustained in groups C (8 weeks) and D (12 weeks; Figure 3b). Concurrently, relative to the control group the Ca2+ spark peak amplitude (ΔF/F) was unchanged in group B, but significantly increased from group C to group D (Figure 3c). The Ca2+ spark decay time constant (Tau) increased significantly and progressively from group B to group D (Figure 3f).
Figure 3

Ca 2+ sparks in groups A-D. (a) Images of Ca2+ sparks; (b) Ca2+ spark frequency; (c) peak amplitude of Ca2+ sparks; (d) FWHM of Ca2+ sparks; (e) rise time; (f) Tau; (g) SR Ca2+ load. *P < 0.05, compared with group A; #P < 0.05, compared with group B; P < 0.05, compared with group C.

In addition, caffeine stimulation caused a sudden and transient Ca2+ release from the SR and an increase in intracellular Ca2+ concentration, which represented the SR Ca2+ load. The SR Ca2+ load showed a marked decline, which was first observed in group B, and declined further in groups C to D (Figure 3g). However, neither the Ca2+ spark rise times nor the full width at half-maximum amplitude (FWHM) were significantly different in the different stages of diabetes from that of the control rats (Figure 3d and e).

Expressions of Ca2+-associated proteins

RyR2, SERCA, and NCX1 are the major channel proteins for Ca2+ flux, and their expressions were analyzed by western blot (Figures 4 and 5). Levels of RyR2 proteins were significantly lower in group B, relative to those of the control, with progressively less in groups C and D (Figure 4b). Expressions of FKBP12.6 protein, a regulatory protein of RyR2, were similar in the control rats and group B, but significantly less in group C, and reduced further in group D (Figure 4c). Both SERCA and NCX1 showed a trend of gradual decline over the 12 weeks in diabetic rats: significantly less in group B relative to the controls, and further declines from group C to group D (Figure 5b, 5c). In addition, expressions of PLB protein, a regulatory protein of SERCA, in group B were similar to those in the control, but significantly and progressively higher levels were detected from group C to group D (Figure 6b). Concurrently, expressions of PLB-Thr17 and PLB-Ser16 proteins were also significantly less in group B relative to the controls, and further declines were detected from group C to group D (Figure 6c, d).
Figure 4

RyR2 and FKBP12.6 in groups A-D. (a) Western blots of RyR2, FKBP12.6, and β-actin; (b) ratios of RyR2 to β-actin; and (c) ratios of FKBP12.6 to β-actin; *P < 0.05, compared with group A; #P < 0.05, compared with group B; P < 0.05, compared with group C.
Figure 5

SERCA and NCX1 in groups A-D. (a) Western blots of SERCA, NCX1, and β-actin; (b) ratios of SERCA to β-actin; and (c) ratios of NCX1to β-actin. *P < 0.05, compared with group A; #P < 0.05, compared with group B; P < 0.05, compared with group C.
Figure 6

PLB, PLB-Thr17 and PLB-Ser16 in groups A-D. (a) Western blots of PLB, PLB-Thr17, PLB-Ser16 and β-actin; Relative ratios of PLB (b), PLB-Thr17 (c) and PLB-Ser16 (d) to β-actin. *P < 0.05, compared with group A; #P < 0.05, compared with group B; P < 0.05, compared with group C.


The present study assessed changes in Ca2+ homeostasis and sarcoplasmic reticulum Ca2+-associated proteins in the development of diabetic cardiomyopathy in a rat model. Over the 12-week experimental period, the cardiac function of the diabetic rats gradually worsened, and this was positively associated with changes in Ca2+ homeostasis. As diabetes progressed, Ca2+ spark properties changed and levels of RyR2, SERCA, NCX1, and FKBP12.6 decreased.

With the development of diabetes, cardiac function of the rats gradually declined. Echocardiography showed impairments of systolic and diastolic functions, reflected by marked reductions in EF, FS, and E/A ratio, which concurrently appeared at the twelfth week.

Hemodynamic measurements are more sensitive than echocardiography in the detection of early cardiac dysfunction. The results of hemodynamic measurements in this study indicated that diastolic and systolic myocardial performance was depressed at the eighth week of diabetes, as determined by significant reductions in ± dP/dtmax. Furthermore, a significant increase in LVEDP appeared at the eighth week of diabetes, earlier than the significant decrease in LVPSP at 12 weeks. These findings suggest that cardiac dysfunction in diabetic rats initially started with left ventricular diastolic function and then proceeded to systolic function, in agreement with previous studies [15]. Furthermore, we noticed that cardiac dysfunction correlated with changes in Ca2+ homeostasis over the 12 weeks.

Our data showed that Ca2+ spark properties experienced a series of changes in a time-dependent manner, associated with the duration of diabetes. The major changes included a gradual decline in both the Ca2+ spark frequency and SR Ca2+ load, and simultaneously an increase in both the Tau and peak amplitude of Ca2+ sparks. Ca2+ spark peak amplitudes and the FWHM reflected the shapes and sizes of Ca2+ sparks in the different diabetic periods. A decrease in Ca2+ spark frequency could indicate a decline in both SR Ca2+ release and global intracellular Ca2+ concentration during excitation-contraction coupling, which might account for, at least in part, the gradual impairment of systolic function in the diabetic rats. An increase in Tau (i.e., the Ca2+ spark decay time constant) could indicate a decline of Ca2+ efflux rate, which might partly account for the reduction of –dP/dtmax, as well as the impairment of diastolic function in the diabetic rats. The SR Ca2+ load gradually declined over the experimental period, and might be partly responsible for the drop in Ca2+ spark frequency in the diabetic rats. It was also noticed that cardiac dysfunction occurred after alterations in Ca2+ handling. This implies that the depression of cardiac function may result, at least in part, from progressive Ca2+ mishandling.

We also showed that levels of the major Ca2+ channel proteins, RyR2, SERCA, and NCX1 declined in a time-dependent manner with the progression of diabetes. Since these declines appeared earlier than Ca2+ mishandling, Ca2+ mishandling could partly result from the changes in channel protein levels. Those of RyR2, the major Ca2+ release channel protein on the SR, exhibited a downward trend in the diabetic rats, which was primarily responsible for the decrease in Ca2+ diffusion away from the SR and Ca2+ spark decay.

Simultaneously, the levels of FKBP12.6, the regulatory protein of RyR2, also declined in a time-dependent manner in the diabetic rats. FKBP12.6 is a small cytosolic protein which binds to the RyR2 protein. The binding stabilizes the RyR2 in the channel’s closed state during diastole [16]. A reduction of FKBP12.6 protein impairs the binding and increases the open state of the RyR2 during diastole, thereby leading to an aberrant increase in diastolic Ca2+ leak [16]. Diastolic Ca2+ leak results in a reduction of SR Ca2+ load and Ca2+ spark frequency, and an increase in the Tau, thereby contributing to the impairment of left ventricular systolic and diastolic functions.

SERCA is another major Ca2+ channel protein on the SR, and is responsible for Ca2+ reuptake (70-92%) into the SR [17]. NCX1 is the major Ca2+ channel protein on sarcolemma, and is responsible for Ca2+ efflux from cardiomyocyte during diastole. Reuptake or efflux of Ca2+ via SERCA or NCX1 decreases the Ca2+ concentration in cardiomyocytes, which facilitates myocardial relaxation and maintains the Ca2+ content in the SR. Decreases in SERCA and NCX1 in this study were primarily the result of intracellular accumulation of Ca2+ during diastole and a prolonged Tau, which corresponded to the impairment of left ventricular diastolic function in the development of diabetes. Moreover, the reduction in SERCA protein was also related to a decrease in the Ca2+ reuptake rate, leading to a decline of SR Ca2+ load.

The regulation of SERCA is dependent on interaction with PLB. It has been confirmed that PLB acts as an inhibitor on SERCA, whereas phosphorylation of PLB can attenuate the inhibition and induce a substantial increase in Ca2+ flux via SERCA [1820]. Upon binding with PLB, SERCA loses activity as Ca2+ reuptake decreases. In the present study, the PLB protein levels progressively increased over the experimental period, and phosphorylation of PLB experienced a gradual decline in the diabetic rats. Both these changes in PLB and its phosphorylation status attenuated the Ca2+ flux by SERCA during diastole in diabetic rats, which was also related to the impairment of left ventricular diastolic function.


The present study showed that Ca2+ sparks decay with progression of diabetes, accompanied by a successive impairment of cardiac function. Alterations in Ca2+ -associated protein levels were detected in the development of diabetes, which partly accounted for the Ca2+ spark decay and subsequent cardiac dysfunction. These results may indicate a possible molecular mechanism underlying cardiac dysfunction in the diabetic rat model, and thereby contribute to the search for a possible intervention. Further studies are warranted to investigate the signal pathways responsible for alterations in the levels of Ca2+-associated proteins.



Ejection fraction


Fractional shortening


Full width at half-maximum amplitude


Left ventricular end-diastolic diameters


Left ventricular end-diastolic pressure


Left ventricular end systolic diameters


Left ventricular systolic peak pressure


Na+/Ca2+ exchanger




Ryanodine receptor 2


Sarcoplasmic reticulum Ca2+-2ATPase


Sarcoplasmic reticulum


Ca2+ spark decay time constant.



The study was supported by National Laboratory of Biomacromolecules, Institute of Biophysics of Chinese Academy, Beijing, and by Start-up funding from Beijing Friendship Hospital (2013). We acknowledge our appreciation of Professor Guang-Ju Ji and his student Qi Yuan for their help in the evaluation of Ca2+ homeostasis.

Authors’ Affiliations

Cardiovascular Center, Beijing Friendship Hospital, Capital Medical University


  1. Fabiato A: Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. Am J Physiol. 1983, 245 (1): C1-C14.PubMedGoogle Scholar
  2. Cheng H, Lederer WJ, Cannell MB: Calcium sparks: elementary events underlying excitation-contraction coupling in heart muscle. Science. 1993, 262 (5134): 740-744. 10.1126/science.8235594.View ArticlePubMedGoogle Scholar
  3. Hasenfuss G, Pieske B: Calcium cycling in congestive heart failure. J Mol Cell Cardiol. 2002, 34 (8): 951-969. 10.1006/jmcc.2002.2037.View ArticlePubMedGoogle Scholar
  4. Luo M, Anderson ME: Mechanisms of altered Ca(2)(+) handling in heart failure. Circ Res. 2013, 113 (6): 690-708. 10.1161/CIRCRESAHA.113.301651.PubMed CentralView ArticlePubMedGoogle Scholar
  5. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A: New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972, 30 (6): 595-602. 10.1016/0002-9149(72)90595-4.View ArticlePubMedGoogle Scholar
  6. Lacombe VA, Viatchenko-Karpinski S, Terentyev D, Sridhar A, Emani S, Bonagura JD, Feldman DS, Gyorke S, Carnes CA: Mechanisms of impaired calcium handling underlying subclinical diastolic dysfunction in diabetes. Am J Physiol Regul Integr Comp Physiol. 2007, 293 (5): R1787-R1797. 10.1152/ajpregu.00059.2007.PubMed CentralView ArticlePubMedGoogle Scholar
  7. Choi KM, Zhong Y, Hoit BD, Grupp IL, Hahn H, Dilly KW, Guatimosim S, Lederer WJ, Matlib MA: Defective intracellular Ca(2+) signaling contributes to cardiomyopathy in type 1 diabetic rats. Am J Physiol Heart Circ Physiol. 2002, 283 (4): H1398-H1408.View ArticlePubMedGoogle Scholar
  8. Yaras N, Sariahmetoglu M, Bilginoglu A, Aydemir-Koksoy A, Onay-Besikci A, Turan B, Schulz R: Protective action of doxycycline against diabetic cardiomyopathy in rats. Br J Pharmacol. 2008, 155 (8): 1174-1184. 10.1038/bjp.2008.373.PubMed CentralView ArticlePubMedGoogle Scholar
  9. Bai SZ, Sun J, Wu H, Zhang N, Li HX, Li GW, Li HZ, He W, Zhang WH, Zhao YJ, Wang LN, Tian Y, Yang BF, Yang GD, Wu LY, Wang R, Xu CQ: Decrease in calcium-sensing receptor in the progress of diabetic cardiomyopathy. Diabetes Res Clin Pract. 2012, 95 (3): 378-385. 10.1016/j.diabres.2011.11.007.View ArticlePubMedGoogle Scholar
  10. Wen HL, Liang ZS, Zhang R, Yang K: Anti-inflammatory effects of triptolide improve left ventricular function in a rat model of diabetic cardiomyopathy. Cardiovasc Diabetol. 2013, 12: 50-10.1186/1475-2840-12-50.PubMed CentralView ArticlePubMedGoogle Scholar
  11. Wang GG, Li W, Lu XH, Zhao X, Xu L: Taurine attenuates oxidative stress and alleviates cardiac failure in type I diabetic rats. Croat Med J. 2013, 54 (2): 171-179. 10.3325/cmj.2013.54.171.PubMed CentralView ArticlePubMedGoogle Scholar
  12. Yaras N, Ugur M, Ozdemir S, Gurdal H, Purali N, Lacampagne A, Vassort G, Turan B: Effects of diabetes on ryanodine receptor Ca release channel (RyR2) and Ca2+ homeostasis in rat heart. Diabetes. 2005, 54 (11): 3082-3088. 10.2337/diabetes.54.11.3082.View ArticlePubMedGoogle Scholar
  13. Picht E, Zima AV, Blatter LA, Bers DM: SparkMaster: automated calcium spark analysis with ImageJ. Am J Physiol Cell Physiol. 2007, 293 (3): C1073-C1081. 10.1152/ajpcell.00586.2006.View ArticlePubMedGoogle Scholar
  14. Li J, Jia BH, Sun J, Lou XL, Hu SJ: Phospholamban antisense RNA improves SR Ca2 + −ATPase activity and left ventricular function in STZ-induced diabetic rats. Biomed Environ Sci. 2013, 26 (7): 577-583.PubMedGoogle Scholar
  15. Piccini JP, Klein L, Gheorghiade M, Bonow RO: New insights into diastolic heart failure: role of diabetes mellitus. Am J Med. 2004, 116 (Suppl 5A): 64S-75S.View ArticlePubMedGoogle Scholar
  16. Marks AR: Ryanodine receptors/calcium release channels in heart failure and sudden cardiac death. J Mol Cell Cardiol. 2001, 33 (4): 615-624. 10.1006/jmcc.2000.1343.View ArticlePubMedGoogle Scholar
  17. Bers DM: Cardiac excitation-contraction coupling. Nature. 2002, 415 (6868): 198-205. 10.1038/415198a.View ArticlePubMedGoogle Scholar
  18. MacLennan DH, Kranias EG: Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol. 2003, 4 (7): 566-577. 10.1038/nrm1151.View ArticlePubMedGoogle Scholar
  19. Mattiazzi A, Mundina-Weilenmann C, Guoxiang C, Vittone L, Kranias E: Role of phospholamban phosphorylation on Thr17 in cardiac physiologi-cal and pathological conditions. Cardiovasc Res. 2005, 68: 366-375. 10.1016/j.cardiores.2005.08.010.View ArticlePubMedGoogle Scholar
  20. Bhupathy P, Babu GJ, Periasamy M: Sarcolipin and phospholamban as regulators of cardiac sarcoplasmic reticulum Ca(2+) ATPase. J Mol Cell Cardiol. 2007, 42: 903-911. 10.1016/j.yjmcc.2007.03.738.PubMed CentralView ArticlePubMedGoogle Scholar


© Zhao et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.